Literature DB >> 11469676

The physiological estrogen metabolite 2-methoxyestradiol reduces tumor growth and induces apoptosis in human solid tumors.

G Schumacher1, P Neuhaus.   

Abstract

2-Methoxyestradiol (2-ME) is a physiological metabolite of estrogen, which is excreted with the urine. In contrast to most estrogens, tumor growth-inhibiting effects were observed. Further studies have revealed that it may be an effective anticancer compound for many tumor types. Several different mechanisms have been attributed to 2-ME. Besides a strong antiangiogenic effect on endothelial cells and tumors, there is a tubulin-inhibiting mechanism, causing cells to arrest in the G2/ M phase of the cell cycle. In other tumors, p53-dependent and p53-independent mechanisms with induction of apoptosis have been shown. The number of different tumors examined for a growth-inhibiting effect is increasing, and new mechanisms are continuously described. In vivo studies in mice, rats, and dogs show no or very little toxicity, even at high doses. Here, we discuss the antitumor activity and their mechanisms. 2-ME appears to be a new anti-tumor compound with strong potential for clinical application.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11469676     DOI: 10.1007/s004320000233

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  11 in total

Review 1.  Sex, Gender, and Sex Hormones in Pulmonary Hypertension and Right Ventricular Failure.

Authors:  James Hester; Corey Ventetuolo; Tim Lahm
Journal:  Compr Physiol       Date:  2019-12-18       Impact factor: 9.090

2.  Urinary estrogen metabolites and prostate cancer risk: a pilot study.

Authors:  Ourania Kosti; Xia Xu; Timothy D Veenstra; Ann W Hsing; Lisa W Chu; Lenka Goldman; Ionut Bebu; Sean Collins; Anatoly Dritschilo; John H Lynch; Radoslav Goldman
Journal:  Prostate       Date:  2010-09-30       Impact factor: 4.104

3.  Reproducibility of fifteen urinary estrogens and estrogen metabolites over a 2- to 3-year period in premenopausal women.

Authors:  A Heather Eliassen; Regina G Ziegler; Bernard Rosner; Timothy D Veenstra; John M Roman; Xia Xu; Susan E Hankinson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-10-20       Impact factor: 4.254

4.  Urinary oestrogen steroidome as an indicator of the risk of localised prostate cancer progression.

Authors:  Jean-Philippe Emond; Louis Lacombe; Patrick Caron; Véronique Turcotte; David Simonyan; Armen Aprikian; Fred Saad; Michel Carmel; Simone Chevalier; Chantal Guillemette; Eric Lévesque
Journal:  Br J Cancer       Date:  2021-04-07       Impact factor: 7.640

5.  Effects of a breast-health herbal formula supplement on estrogen metabolism in pre- and post-menopausal women not taking hormonal contraceptives or supplements: a randomized controlled trial.

Authors:  Maggie Laidlaw; Carla A Cockerline; Daniel W Sepkovic
Journal:  Breast Cancer (Auckl)       Date:  2010-12-16

6.  DNA strand breaks induced by nuclear hijacking of neuronal NOS as an anti-cancer effect of 2-methoxyestradiol.

Authors:  Magdalena Gorska; Alicja Kuban-Jankowska; Michal Zmijewski; Antonella Marino Gammazza; Francesco Cappello; Maciej Wnuk; Monika Gorzynik; Iwona Rzeszutek; Agnieszka Daca; Anna Lewinska; Michal Wozniak
Journal:  Oncotarget       Date:  2015-06-20

7.  Comparison of metabolic ratios of urinary estrogens between benign and malignant thyroid tumors in postmenopausal women.

Authors:  Ju-Yeon Moon; Eun Jig Lee; Woong Youn Chung; Myeong Hee Moon; Bong Chul Chung; Man Ho Choi
Journal:  BMC Clin Pathol       Date:  2013-10-25

8.  The in vitro effects of a novel estradiol analog on cell proliferation and morphology in human epithelial cervical carcinoma.

Authors:  Laura Susan Boyd; Devrim Gozuacik; Anna Margaretha Joubert
Journal:  Cell Mol Biol Lett       Date:  2018-03-20       Impact factor: 5.787

9.  Opposite regulation of XIAP and Smac/DIABLO in the rat endometrium in response to 17beta-estradiol at estrus.

Authors:  Valerie Leblanc; Marie-Claude Dery; Carl Shooner; Eric Asselin
Journal:  Reprod Biol Endocrinol       Date:  2003-08-27       Impact factor: 5.211

10.  ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization in vivo.

Authors:  Christian Moser; Sven A Lang; Akira Mori; Claus Hellerbrand; Hans J Schlitt; Edward K Geissler; William E Fogler; Oliver Stoeltzing
Journal:  BMC Cancer       Date:  2008-07-23       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.